MAKO Surgical (Nasdaq: MAKO) is expected to report Q2 earnings on Aug. 1. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MAKO Surgical's revenues will increase 27.3% and EPS will remain in the red.

The average estimate for revenue is $23.7 million. On the bottom line, the average EPS estimate is -$0.22.

Revenue details
Last quarter, MAKO Surgical logged revenue of $19.6 million. GAAP reported sales were 51% higher than the prior-year quarter's $13.0 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, EPS came in at -$0.28. GAAP EPS were -$0.28 for Q1 versus -$0.27 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 72.1%, 350 basis points better than the prior-year quarter. Operating margin was -59.9%, 2,490 basis points better than the prior-year quarter. Net margin was -59.7%, 2,470 basis points better than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $109.0 million. The average EPS estimate is -$0.79.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,126 members out of 1,167 rating the stock outperform, and 41 members rating it underperform. Among 252 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 238 give MAKO Surgical a green thumbs-up, and 14 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $42.25.

The healthcare investing landscape is littered with also-rans and a few major winners. Is MAKO Surgical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.